Skip to main content
. Author manuscript; available in PMC: 2016 May 1.
Published in final edited form as: Ophthalmology. 2015 Feb 14;122(5):1008–1015. doi: 10.1016/j.ophtha.2014.12.017

Table 2.

Retinopathy of prematurity recurrence rates in intravitreal bevacizumab (IVB) and panretinal photocoagulation groups (PRP)

No of Eyes
with
Recurrence
(%)
Type Outcome
IVB 3/22 (14%)
- Zone 1 3/16 (19%) Plus (n=2) NVI* (n=1) regressed after laser photocoagulation (n=2) regressed after second IVB (n=1)
- Zone 2 0/6 (0%)
PRP 1/32 (3%)
- Zone 1 1/5 (20%) RD** Stage 5 retinal detachment
- Zone 2 0/27 (0%)
*

NVI = neovascularization of the iris

**

RD = retinal detachment